Chr. Hansen sets a price of DKK 90 per share for its Initial Public Offering

Company announcement no.3/2010, June 3, 2010

NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH
AFRICA

Chr. Hansen sets a price of DKK 90 per share for its Initial Public Offering    

Chr. Hansen Holding A/S (“Chr. Hansen”, or the “Company”), a global supplier of
bioscience-based ingredients to the food, health and animal feed industries,
today announces an offer price of DKK 90 per share in respect of its Initial
Public Offering (“IPO”, or the “Offering”) of new and existing shares (“Offer
Shares”). Admission to trading and official listing on NASDAQ OMX Copenhagen
will take place today, June 3, 2010, under the symbol “CHR”. 

Summary of the Offering                                                         

- Despite volatile markets, the Offering has attracted strong demand from
Danish and international institutional investors, as well as from Danish retail
investors 
- The price of DKK 90 per Offer Share gives Chr. Hansen a market capitalisation
of DKK 12,423 million 
- The Offering (prior to any exercise of the over-allotment option) totals DKK
5,019 million, with a free float of 38.3%. If the over-allotment option is
exercised in full the Offering size will be DKK 5,521 million, with a free
float of 42.3% 
- Based on a price of DKK 90, 37,209,000 new shares will be issued by the
Company, raising net proceeds of approximately DKK 3,152 million. Additionally,
18,561,732 existing shares will be sold by Financière Star 1 S.A. (the “Selling
Shareholder”) 
- The Selling Shareholder has granted the Joint Global Coordinators (on behalf
of the Managers) an over-allotment option over a further 5,577,074 existing
shares with a value of DKK 501.9 million at the offer price, which is
exercisable in whole or in part up to July 3, 2010 
- Further details may be found in appendix 1 (“Pricing Statement”) 

The Offering was met with substantial interest from Danish retail and Danish
and international institutional investors. The retail offering was closed after
five days. Approximately 5,000 investors have been allocated shares in
Chr. Hansen. Approximately 10% of the Offering (6.1m Offer Shares) were sold to
retail investors in Denmark, with the remaining shares being allocated to
Danish and international institutional investors. 

The Selling Shareholder will hold 82,263,488 shares, comprising 59.6% of the
Company's share capital following completion of the Offering, or 76,686,414
shares comprising 55.6% of the Company's share capital if the over-allotment
option is fully exercised. 

Admission to trading and official listing on NASDAQ OMX Copenhagen will take
place today. The Company's ticker is CHR. The Company's shares have the ISIN
code DK0060227585. 

A total of 2,894,034 existing shares have been allocated to the Company in
order to deliver shares pursuant to the Company's management incentive programs
and a total of 64,441 existing shares have been allocated to members of Chr.
Hansen's Board of Directors to purchase at the offer price in connection with
the Offering. 

In respect of orders for amounts of up to DKK 3 million, reductions have been
made mathematically as follows: 
- Orders for up to and including 555 shares, corresponding to DKK 49,950, have
been allocated in full; 
- Orders for up to and including 5,555 shares, corresponding to DKK 499,950,
have been allocated 555 shares and 60% of the remaining order; 
- Orders for more than 5,555 shares have been allocated 3,555 shares and 30% of
the remaining order above 5,555 shares. 
Allocations in respect of orders for amounts of up to DKK 3 million have been
rounded up to the nearest whole number of shares. 

In respect of orders for amounts of more than DKK 3 million, individual
allocations will be made by the Selling Shareholder and the Company's Board of
Directors, following consultation with the Joint Bookrunners. 

The Offer Shares are expected to be delivered on or about June 8, 2010 (the
“Closing Date”) against payment in immediately available funds in Danish
kroner. The Offer Shares will be delivered in book-entry form on the Closing
Date to 
investors' accounts with VP Securities and through the facilities of Euroclear
Bank, S.A./N.V. and Clearstream Banking S.A. 

Credit Suisse Securities (Europe) Ltd and J.P. Morgan Securities Ltd. are
acting as Joint Global Coordinators, while Credit Suisse, Danske Markets
(Division of Danske Bank A/S), J.P. Morgan, Morgan Stanley & Co. International
plc and SEB Enskilda (part of Skandinaviska Enskilda Banken AB (publ)) are
acting as Joint Bookrunners and Carnegie Bank A/S and Crédit Agricole Corporate
and Investment Bank are acting as Co-Lead Managers. 

Lars Frederiksen, CEO of Chr. Hansen commented:                                 

“We are very pleased with the substantial interest we have received from retail 
and institutional investors in Denmark and institutional investors              
internationally, particularly in light of the recent market turbulence. We see  
this as a strong sign of confidence in our business model and our plans for the 
next phase of growth. We are delighted to welcome the approximately 5,000 new   
shareholders, and are at the same time pleased to be able to continue the       
successful collaboration with PAI partners who have retained a considerable     
stake in the company.”                                                          
                                                                                

Frédéric Stévenin, Partner at PAI partners, commented:                          

“We are delighted with the outcome achieved today, confirming what has long been
our belief, that Chr. Hansen is an attractive proposition for investors. Working
closely with the management, we have built a dynamic, market leading business   
that has significant growth potential. We believe that Chr. Hansen has a strong 
future ahead of it as a publicly listed company and will be retaining a         
significant stake in the business going forward.”                               

For further information, please contact:                                        

Ole Andersen, Chairman                                                          
Tel: +45 4574 7623                                                              

Lars Frederiksen, CEO                                                           
Tel: +45 4574 7474                                                              

Ulrik R. Søndergaard, Corporate Communications                                  
Tel: +45 4574 7109                                                              


About Chr. Hansen                                                               
Chr. Hansen is a global bioscience company that develops natural ingredient     
solutions for the food, nutritional, pharmaceutical and agricultural industries.
All solutions are based on strong research and development competencies and     
significant technology investments. The company enjoys market leadership in all 
its divisions: Cultures & Enzymes, Health & Nutrition and Colors & Blends. There
are more than 2,200 dedicated employees in over 30 countries. For further       
information, please visit www.chr-hansen.com.                                   


DISCLAIMER                                                                      

The securities being offered have not been, and will not be, registered under   
the United States Securities Act of 1933, as amended (the "U.S. Securities Act")
or any U.S. state securities laws, and may not be offered or sold in the United 
States absent registration or any applicable exemption from the registration    
requirement of the U.S. Securities Act and applicable U.S. state securities     
laws.                                                                           

This release shall not constitute an offer to sell, or the solicitation of an   
offer to buy securities in the United States. The information contained herein  
does not constitute an offer to sell or the solicitation of an offer to buy nor 
shall there be any sale of the securities referred to herein in the United      
States or any jurisdiction in which such offer, solicitation or sale would be   
unlawful prior to registration, exemption from registration or qualification    
under the securities laws of any jurisdiction.                                  

No public offer of securities is made outside of Denmark. Any offer of          
securities that may be deemed to be made pursuant to this communication in any  
EEA Member State that has implemented Directive 2003/71/EC (together with any   
applicable implementing measures in any Member State, the "Prospectus           
Directive") is only addressed to and is only directed at qualified investors in 
that Member State within the meaning of the Prospectus Directive.               

These materials are only being distributed to and are only directed at (i)      
persons who are outside the United Kingdom, subject to applicable laws or (ii)  
persons who have professional experience in matters relating to investments     
falling within the definition of "investment professionals" in Article 19(5) of 
the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005    
(the "Order"), and (iii) high net worth entities, and other persons to whom it  
may lawfully be communicated, falling within Article 49(2) of the Order (all    
such persons together being referred to as "relevant persons"). Any investment  
or investment activity to which these materials relate will only be available to
and will only be engaged with, relevant persons. Any person who is not a        
relevant person should not act or rely on this document or any of its contents. 

This announcement may contain forward-looking statements including statements   
pertaining to the timing of the Offering, the exercise of the over-allotment    
option, the settlement and delivery of the Offer Shares, the growth prospects of
the Company, the Company's collaboration with PAI partners, the Selling         
Shareholder‘s ownership interest in the Company, the first day of trading and   
the capital structure of the Company upon completion of the Offering. These     
statements are based on current expectations that involve a number of risks and 
uncertainties which could cause actual results to differ from those anticipated.
A number of factors could cause actual results and developments to differ       
materially from those expressed or implied by the forward-looking statements    
including, without limitation: conditions in the markets; the financial         
position, cash flows and liquidity of the Company; changing business or other   
market conditions; and general economic conditions. These and other factors     
could adversely affect the outcome and financial effects of the plans and events
described in the documents or other information contained herein.               
Forward-looking statements contained in the documents or other information      
contained herein based on past trends or activities should not be taken as a    
representation that such trends or activities will continue in the future. Save 
as required by law, the Company does not undertake any obligation to update or  
revise any forward-looking statements, whether as a result of new information,  
future events or otherwise. You should not place undue reliance on              
forward-looking statements, which are applicable only as at the date they are   
made.